Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)

Overweight Clinical Trial

Official title:

A Two Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of Twice-Daily Repeat Intake of 1110 mg of Hoodia Gordonii Purified Extract (PYM50717)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01306422
• Other study ID #: 07044V
• Status: Completed
• Phase: N/A
• First received: February 25, 2011
• Last updated: February 28, 2011
• Start date: March 2008
• Est. completion date: October 2008

Study information

• Verified date: February 2011
• Source: Unilever R&D
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical study was to assess the safety, tolerability, efficacy (effects on appetite scores, food intake) and plasma kinetics of Hoodia gordonii purified extract (H.g.PE), when consumed twice-daily for 2 or 15-days.

Description:

A two stage randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, kinetics and efficacy of twice-daily repeat intake of formulated Hoodia gordonii purified extract (H.g.PE) (PYM50717) administered twice daily for 2 or 15 days to healthy, overweight females aged 18 to 50 years with a body fat of 25-45%.

Stage 1 (pilot): Placebo controlled, double blind comparison to assess the effect of timing of product administration (i.e. breakfast and lunch vs breakfast and dinner).

Stage 2 (main study): Placebo controlled double blind comparison with product administered with breakfast and dinner.

A total of 64 subjects were included in this study; stage 1: n=15, stage 2: n=49. Treatment groups in stage 2 were matched for percentage body fat.

Stage 1:

• H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch (n = 4).

• Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch (n = 3).

• H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner (n = 5).

• Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner (n = 3).

Stage 2:

• H.g.PE formulated product (1110 mg), twice daily (n=25)for 15 days

• Placebo product , twice daily (n=24),for 15 days

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: October 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy females between the ages of 18 and 50 years.

• Body fat between 25% and 45% as assessed by Dual Energy X-ray absorptiometry (DEXA) scan at Screening.

• Stable body weight for at least two months prior to Screening (weight loss or gain >5% was considered unstable).

• Regularly consumed at least three meals per day, including breakfast.

• Agreed to abstain from strenuous exercise throughout the entire study.

Exclusion Criteria:

• Subjects who were pregnant, lactating or were not willing to use two contraceptives (including at least one barrier contraceptive) starting at least 14 days before study product administration (Day 1) and until at least 30 days following study product administration (except subjects who were surgically sterilized or were more than one year post-menopausal).

• Subjects who were taking any prescription or over the counter medications (with the exception of hormonal contraceptives) (including supplements, especially as related to weight management [eg, ephedrine, caffeine, synephrine]) within one week prior to Visit 2 (Day 1), or antibiotics <3 months prior to Day 1, or planned to do so during the course of the study.

• Smokers, or ex-smokers who smoked any cigarettes in the past six months prior to study product administration and/or who used another form of nicotine-containing product.

• Fasting blood glucose > 7 mmol/L (126 mg/dL) at Screening.

• Psychiatric disorders that could have interfered with the subject's compliance to the requirements of the protocol, at the discretion of the Investigator.

• Used or planned to use any medically prescribed diet or weight-loss diet or made any attempt to control diet at Screening and during the entire study.

• Strenuous exercise >5 hours per week (eg, sports).

• Restrained eating behavior determined by a score of =16 on the Revised Restraint Scale

• a low score on the Food Action Rating Scale

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Appetite Depressant
• Body Weight
• Overweight

Intervention

Other:
• Hoodia gordonii purified extract (H.g.PE)
H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
• Placebo yogurt drink
Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
• Placebo yogurt drink
Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
• Placebo yogurt drink
Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
• Hoodia gordonii purified extract (H.g.PE)
H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
• Hoodia gordonii purified extract (H.g.PE)
H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner

Locations

Country	Name	City	State
United States	Covance CRU	Madison	Wisconsin

Sponsors (3)

Lead Sponsor	Collaborator
Unilever R&D	Covance, Phytopharm

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of 2 and 15 day repeat consumption of Hoodia gordonii Purified Extract (H.g.PE)	Safety and tolerability (Adverse Events (AEs), vitals signs, Electrocardiogram (ECG), laboratory assessments) of twice daily consumption of 1110 mg of formulated Hoodia gordonii purified extract (H.g.PE) consumed over a period of 2 or 15 days were assessed up to 41 days after start of the intervention	41 days	Yes
Primary	Efficacy of 15-day repeat consumption of H.g.PE	Efficacy of twice daily consumption of 1110 mg of formulated H.g.PE during 15-day repeat intake was assessed. Appetite scores, ad libitum energy intake, body weight and body composition were assessed during the 15-day intervention.	15 days	No
Secondary	Assessment of the pharmacokinetics of PYM50057 a marker of the steroid glycosides in H.g.PE	Kinetic parameters were calculated on Days 5 and 19 based on the individual plasma concentration-time profiles of the steroid glycoside, PYM50057. Maximum measured plasma concentration (Cmax), time of Cmax (tmax), area under the concentration-time curve (AUC), apparent terminal phase rate constant (Kel), absorption rate constant (Ka),the apparent first order elimination rate constant (?z) and the overall apparent elimination half-life (t1/2) were assessed. Samples were taken up to 41 days after start of the intervention.	41 days	No